Pharming Group
Pharming Group's revenue rose 26.6% to $376 million in fiscal 2025. Its operating margin was 6.9%, up from −2.9% a year earlier. Free cash flow was $54 million. The diluted share count fell 4.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
Income statement
From fiscal 2019 to 2022, earnings per share fell 30.7% a year and net income 30.4% a year, as new shares raised the share count by 5% and diluted each share's earnings. Pharming Group then lost money in fiscal 2023 and 2024.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 192 | 207 | 62 | 55 | 145 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | 144.3x | 173.7x | −40.2x | −153.9x | 131.8x |
| Current ratio | 5.3x | 4.7x | 4.1x | 3.8x | 2.6x |
| Quick ratio | 4.8x | 3.9x | 3.3x | 3.0x | 2.0x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 11.7% | 20.3% | 40.9% |
| Altman Z'' | 2.37 | 2.26 | 2.28 |
| Accruals ratio | 1.5% | −2.3% | −11.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Pharming Group side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Pharming Group | FY25 | 26.6% | 6.9% | 14.3% | — | — | — | |
| Arcutis Biotherapeutics | FY25 | 91.3% | −3.2% | −1.7% | −16.9% | — | 4 | Compare |
| Sinovac Biotech | FY25 | 6.8% | −127.0% | −145.4% | — | — | 3 | Compare |
| MannKind | FY25 | 22.2% | 11.1% | 3.9% | — | 3.6x | 4 | Compare |
| Ardelyx | FY25 | 22.1% | −10.1% | −10.8% | −36.1% | — | 2 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | 189 | 212 | 199 | 206 | 245 | 297 | 376 |
| Revenue growth | — | — | 12.0% | −6.3% | 3.4% | 19.3% | 21.1% | 26.6% |
| Gross profit | — | 166 | 189 | 178 | 188 | 220 | 262 | 331 |
| Research and development | — | 32 | 38 | 70 | 52 | 69 | 83 | 100 |
| Operating income | — | 68 | 76 | 14 | 18 | −5 | −9 | 26 |
| Net income | — | 41 | 38 | 16 | 14 | −10 | −12 | 3 |
| Diluted EPS (US$) | — | 0.06 | 0.06 | 0.02 | 0.02 | −0.02 | −0.02 | 0.00 |
| Diluted shares (millions) | 654 | 674 | 683 | 701 | 707 | 726 | 785 | 747 |
| Cash flow | ||||||||
| Cash from operations | — | 74 | 84 | 38 | 22 | −17 | −2 | 55 |
| Capital expenditure | — | 3 | 5 | 11 | 1 | 1 | 1 | 1 |
| Free cash flow | — | 72 | 79 | 27 | 21 | −19 | −3 | 54 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58 |
| Stock-based compensation | — | 4 | 6 | 9 | 6 | 9 | 11 | 14 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 92 | 74 | 205 | 192 | 207 | 62 | 55 | 145 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — |
| Total assets | — | 256 | 418 | 397 | 426 | 463 | 400 | 500 |
| Total liabilities | — | 138 | 235 | 204 | 221 | 244 | 179 | 223 |
| Shareholders' equity | 64 | 117 | 183 | 193 | 205 | 219 | 221 | 277 |
| Margins and ratios | ||||||||
| Gross margin | — | 87.4% | 88.9% | 89.4% | 91.5% | 89.7% | 88.1% | 87.9% |
| Operating margin | — | 36.0% | 35.9% | 6.8% | 8.9% | −2.2% | −2.9% | 6.9% |
| Net margin | — | 21.4% | 17.8% | 8.0% | 6.7% | −4.3% | −4.0% | 0.8% |
| Free cash flow margin | — | 37.8% | 37.2% | 13.6% | 10.2% | −7.6% | −0.9% | 14.3% |
| Rule of 40 (growth + FCF margin) | — | — | 49.2% | 7.4% | 13.7% | 11.7% | 20.3% | 40.9% |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | — | 25.1% | 8.5% | 6.9% | −5.0% | −5.4% | 1.1% |
| Return on assets | — | — | 11.2% | 3.9% | 3.3% | −2.4% | −2.7% | 0.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |